A Major Shareholder at Ophthotech Corp (NASDAQ: OPHT) is Selling Shares

By Carrie Williams

Today, a Major Shareholder at Ophthotech Corp (NASDAQ: OPHT), A S Novo, sold shares of OPHT for $17.59M.

The company has a one year high of $80 and a one year low of $4.53. Currently, Ophthotech Corp has an average volume of 9.74M.

Based on 9 analyst ratings, the analyst consensus is Hold with an average price target of $36.67, reflecting a -85.8% downside.

The insider sentiment on Ophthotech Corp has been positive according to 33 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

Ophthotech Corp. operates as a biopharmaceutical company. It focuses on discovering, developing and commercializing novel therapeutics to treat diseases of the back of the eye. It develops therapies for age-related macular degeneration. Its product candidates include Fovista Anti platelet derived growth factor Therapy, Zimura Anti-Complement and Aptamer Technology. The company was founded on January 5, 2007 by David R. Guyer and Samir Chandrakant Patel and is headquartered in New York, NY.